Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Jiafu Ji, Yanong Wang et al.|The Lancet Oncology|2021Cited by 436
Tumorigenicity and prediction of clinical prognosis of patient‐derived gastric cancer organoidsT. H. Wang, Ye‐Guang Chen, Wanlu Song et al.|Clinical and Translational Medicine|2024Cited by 6